SAN DIEGO, Calif., Jan. 23, 2015 – Pathway Genomics Corporation (“Pathway”) today announced a settlement agreement that ends the BRCA patent litigation against Pathway that began on June 13, 2014.
Under the agreement, Myriad Genetics, Inc., the University of Utah Research Foundation, HSC Research and Development Limited Partnership, Endorecherche, Inc., and the Trustees of the University of Pennsylvania (the “Patent Owners”) and Pathway dismiss their respective claims and counterclaims against one another in the BRCA patent litigation. Additionally, the Patent Owners granted a covenant to not sue Pathway under the patents asserted in the litigation proceedings.
“We are very pleased to close this chapter and continue our focus on providing innovative cancer risk testing to patients around the world,” said Jim Plante, Pathway Genomics’ founder and CEO.
The decision to settle follows an opinion from the United States Court of Appeals for the Federal Circuit on Dec. 17, 2014 that ruled some of the key patent claims at issue in the case were directed to ineligible subject matter under 35 U.S.C. §101.
The case is University of Utah Research Foundation et al. v. Pathway Genomics Corporation, Case No. 2:14-cv-442-RJS and MDL Case No. 2:14-MD-02510, in the U.S. District Court for the District of Utah.
About Pathway Genomics Corporation
As a CLIA and CAP accredited clinical laboratory based in San Diego, California, Pathway Genomics provides physicians and their patients with actionable and accurate genetic information to improve or maintain health and wellness. Since its founding in 2008, Pathway Genomics has become known for its dedication to innovation and commitment to medical responsibility – making it a leader in the commercial genetic testing industry. Pathway Genomics’ testing services cover a variety of conditions including cancer risk, cardiac health, inherited diseases, nutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health. For more about Pathway Genomics, visit www.pathway.com.
Pathway Genomics, the Pathway Genomics logo, BRCATrue, BreastTrue High Risk Panel, Cardiac DNA Insight, Cardiac Healthy Weight DNA Insight, Carrier Status DNA Insight, ColoTrue, Healthy Weight DNA Insight, Healthy Woman DNA Insight, Mental Health DNA Insight, Pain Medication DNA Insight, and Pathway Fit are registered trademarks of Pathway Genomics Corporation in the United States and other jurisdictions.